Elamipretide trial shows encouraging results in improving cardiac function in Barth syndrome patients.
A Phase 2/3 TAZPOWER study evaluating elamipretide in patients with Barth syndrome (a type of mitochondrial disease) has shown encouraging results in the improvement of cardiac function.
"Based on the data presented showing an increase in stroke volume, treatment with elamipretide appears to have improved heart function, which might indicate cardiac remodelling," noted Dr. W. Reid Thompson, Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine. "Most patients with Barth syndrome have underlying heart disease, so a cardiac effect would be an important outcome in this setting that warrants further investigation."
Other elamipretide clinical trials focusing on different types of mito, including Primary Mitochondrial Myopathy are currently taking place.
Each clinical trial, brings us a step closer to effective treatments and hope for the future.
Photo by Robina Weermeijer on Unsplash
